NCT02271399View on ClinicalTrials.gov

Comparative Study of Prophylactic Agent for Venous Thromboembolism After Total Knee Arthroplasty

PHASE2CompletedINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

January 31, 2016

Study Completion Date

February 29, 2016

Conditions
Venous Thromboembolism
Interventions
DRUG

acetylsalicylic acid

300 mg aspirin(acetylsalicylic acid, AA, Bayer)/day was given orally for 10 days postoperatively.

DRUG

rivaroxaban

xarelto 10mg(rivaroxaban, AA, Bayer)/day was given orally for 10 days postoperatively

Trial Locations (1)

133-792

Department of Orthopaedic Surgery, Hanyang University, College of Medicine, Seoul

All Listed Sponsors
lead

Hanyang University Seoul Hospital

OTHER

NCT02271399 - Comparative Study of Prophylactic Agent for Venous Thromboembolism After Total Knee Arthroplasty | Biotech Hunter | Biotech Hunter